Molecular therapy for pulmonary arterial hypertension: Melatonin inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 12.02 pm
What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist […]
Molecular therapy for pulmonary arterial hypertension: Fenofibrate inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 10/February/2018, 11.23 pm
What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist […]
Carbon monoxide-based therapy for pulmonary arterial hypertension: COR-M2 (CO (Carbon monoxide) Releasing Molecules-2) inhibits the development of pulmonary arterial hypertension via up regulation of its target gene Notch3, 10/February/2018, 7.31 am
What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist […]
Molecular therapy for pulmonary arterial hypertension: Rampril (brand name: Altace), an angiotensin-converting enzyme inhibitor used to treat high blood pressure and myocardial disorders, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 29/January/2018, 10.42 pm
What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist […]
Molecular therapy for pulmonary arterial hypertension: Clopidogrel(brand name: Plavix), a drug used to treat myocardial disorders, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 28/January/2018, 10.19 pm
What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist […]
Molecular therapy for pulmonary arterial hypertension: Pantoprazole (Brand name: Protonex), a drug used to treat stomach and intestinal ulcers, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 27/January/2018, 11.30 pm
What they say: A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others. What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist […]
